SNPMiner Trials by Shray Alag


SNPMiner Trials: Clinical Trial Report


Report for Clinical Trial NCT02167165

Developed by Shray Alag, 2019.
SNP Clinical Trial Gene

Role of Genetic Factors in the Response to Digoxin in the Acute Treatment of Atrial Fibrillation

This study tested the hypothesis that response to digoxin is modulated by single Nucleotid Polymorphism (SNP): - Multi Drug Resistance (MDR1) gene haplotypes and Solute carrier organic anion transporter family member 1B3 (SLCO1B3) gene Polymorphism and their role in the response to treatement. - Aldosterone synthase (CYP11B2) gene and sodium channel, voltage-gated, type V alpha subunit gene (SCN5A) correlated with atrial fibrillation and their roles in response to digoxin.

NCT02167165 Atrial Fibrillation
MeSH: Atrial Fibrillation
HPO: Atrial fibrillation Paroxysmal atrial fibrillation

1 Interventions

Name: Digoxin

Description: Patients consulting the ED for Acute onset AF received 0.5 mg digoxin by oral root

Type: Drug

Digoxin and AF


Primary Outcomes

Description: In the current study we aimed at outlining the different MDR-1, SLCO1B3, CYP11B12 and SCN5A genotypes in a sample of Tunisian patients, suffering from AF and taking digoxin, to assess the role of SNPs in affecting serum digoxin concentrations, and studying the consequences on patients' clinical outcome. Patients will be monitored for 24 hours in an intensive care unit;

Measure: Correlation between the response to digoxin and the genotypes of the patients

Time: 24 hours

Secondary Outcomes

Description: Rhythm control: rate and delay of return to sinusal rhythm. Rate control: reduction of heart rate : HR <100 bpm or 20% reduction from baseline

Measure: Rhythm and Rate control

Time: 24 hours

Other Outcomes

Measure: Arterial hypotension Bradycardia (HR <45 bpm) Other (chest pain, allergic reaction……)

Time: 24 hours

Time Perspective: Prospective

Case Control


There are 8 SNPs

SNPs


1 A893S

The aim of the current study is to analyze the ABCB1: C1236T (Gly412Gly), G2677>T⁄A (Ala893Ser/ Thr) and C3435T (Il1145Ile) polymorphisms. --- C1236T --- --- Ala893Ser ---


2 C1236T

The aim of the current study is to analyze the ABCB1: C1236T (Gly412Gly), G2677>T⁄A (Ala893Ser/ Thr) and C3435T (Il1145Ile) polymorphisms. --- C1236T ---


3 C3435T

The aim of the current study is to analyze the ABCB1: C1236T (Gly412Gly), G2677>T⁄A (Ala893Ser/ Thr) and C3435T (Il1145Ile) polymorphisms. --- C1236T --- --- Ala893Ser --- --- C3435T ---


4 G699A

In this study we will also investigate the relationship between two deletion polymorphisms (from -28 to -11 deletion) and (from-7 to -4 deletion), T334G (Ser112Ala) and G699A (Met233Ile) SNPs in the SLCO1B3gene and their role in response to digoxin. --- T334G --- --- Ser112Ala --- --- G699A ---


5 H558R

We hypothesized that the T-344C and H558R (His558Arg) SNPs in CYP11B2 and SCN5A gene which are associated with susceptibility to AF could be implicated in the variation of response to Digoxin. --- H558R ---

We hypothesized that the T-344C and H558R (His558Arg) SNPs in CYP11B2 and SCN5A gene which are associated with susceptibility to AF could be implicated in the variation of response to Digoxin. --- H558R --- --- His558Arg ---


6 M233I

In this study we will also investigate the relationship between two deletion polymorphisms (from -28 to -11 deletion) and (from-7 to -4 deletion), T334G (Ser112Ala) and G699A (Met233Ile) SNPs in the SLCO1B3gene and their role in response to digoxin. --- T334G --- --- Ser112Ala --- --- G699A --- --- Met233Ile ---


7 S112A

In this study we will also investigate the relationship between two deletion polymorphisms (from -28 to -11 deletion) and (from-7 to -4 deletion), T334G (Ser112Ala) and G699A (Met233Ile) SNPs in the SLCO1B3gene and their role in response to digoxin. --- T334G --- --- Ser112Ala ---


8 T334G

In this study we will also investigate the relationship between two deletion polymorphisms (from -28 to -11 deletion) and (from-7 to -4 deletion), T334G (Ser112Ala) and G699A (Met233Ile) SNPs in the SLCO1B3gene and their role in response to digoxin. --- T334G ---



HPO Nodes


HPO:
Atrial fibrillation
Genes 62
CACNA1C KCNE2 MFAP5 CACNA2D1 TNNI3K FLNC GJA5 NPPA CACNB2 MYH7 MYL4 KCNA5 ANK2 NUP155 LMNA SLC25A4 HCN4 DTNA KCNH2 KCNJ2 FOS KCNJ5 RRM2B POLG SCN1B TLL1 SCN2B MYPN SCN4B AGPAT2 SCN5A MYOZ2 GATAD1 KCNQ1 NKX2-5 ABCC9 TWNK CASQ2 TAB2 XK CAVIN1 BSCL2 TMEM43 GATA5 ACTN2 CAV1 PPARG PRKAG2 TNNC1 DMPK POLG2 TNNI3 SGO1 TNNT2 PLN NEXN TRDN TTN CSRP3 RYR2 SMAD3 TBX5
Paroxysmal atrial fibrillation
Genes 12
CSRP3 KCNJ5 SCN1B SCN2B KCNE2 MYL4 SCN5A ABCC9 KCNA5 PRKAG2 TBX5 KCNJ2